FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1797-1810 June 23, 1994 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Twenty years ago, the discovery of a deficit of acetylcholine receptors at the neuromuscular junctions of patients with myasthenia gravis¹ and the development of an animal model of the disease² shed new light on a disorder that was first described clinically 300 years earlier by the great physiologist Thomas Willis³. During the past two decades, remarkable progress has been made in our understanding of myasthenia gravis, and the new knowledge has been applied directly to the clinical diagnosis and treatment of this formerly grave disease. Myasthenia gravis is undoubtedly the most thoroughly understood of all human autoimmune diseases and . . . [Full Text of this Article]

Clinical Features

The Neuromuscular Junction in Myasthenia Gravis

The Acetylcholine Receptor

Immunopathogenesis of Myasthenia Gravis

Antibody-Mediated Mechanisms

Accelerated Degradation of Acetylcholine Receptors

Blockade of Acetylcholine Receptors

Damage to Neuromuscular Junctions

Functional Properties of Anti-Acetylcholine-Receptor Antibodies and the Severity of Disease

Properties of Acetylcholine-Receptor Antibodies

"Antibody-Negative" Myasthenia Gravis

Role of Lymphocytes in Myasthenia Gravis

Origin of the Autoimmune Response in Myasthenia Gravis

Diagnosis

Diagnostic Testing

Differential Diagnosis

Search for Associated Conditions

Treatment

Anticholinesterase Agents

Thymectomy

Immunosuppressive Treatment

            Corticosteroids

            Azathioprine

            Cyclosporine

Short-Term Immunotherapies: Plasma Exchange and Intravenous Immune Globulin

Specific Immunotherapy: The Future of Treatment

B-Cell-Directed Approaches

T-Cell-Directed Approaches

Conclusions

Source Information

From the Department of Neurology, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287-7519, where reprint requests should be addressed to Dr. Drachman.

References

This article has been cited by other articles:

• Leite, M. I., Jacob, S., Viegas, S., Cossins, J., Clover, L., Morgan, B. P., Beeson, D., Willcox, N., Vincent, A. (2008). IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131: 1940-1952 [Abstract] [Full Text]  
• VERNINO, S. (2008). Neuronal Acetylcholine Receptor Autoimmunity. Ann. N. Y. Acad. Sci. 1132: 124-128 [Abstract] [Full Text]  
• MERIGGIOLI, M. N., SHENG, J. R., LI, L., PRABHAKAR, B. S. (2008). Strategies for Treating Autoimmunity: Novel Insights from Experimental Myasthenia Gravis. Ann. N. Y. Acad. Sci. 1132: 276-282 [Abstract] [Full Text]  
• DRACHMAN, D. B., ADAMS, R. N., HU, R., JONES, R. J., BRODSKY, R. A. (2008). Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis. Ann. N. Y. Acad. Sci. 1132: 305-314 [Abstract] [Full Text]  
• RUCKERT, J. C., ISMAIL, M., SWIERZY, M., SOBEL, H., ROGALLA, P., MEISEL, A., WERNECKE, K. D., RUCKERT, R. I., MULLER, J. M. (2008). Thoracoscopic Thymectomy with the da Vinci Robotic System for Myasthenia Gravis. Ann. N. Y. Acad. Sci. 1132: 329-335 [Abstract] [Full Text]  
• Toker, A., Tanju, S., Ozluk, Y., Serdaroglu, P. (2008). Thymoma appearing 10 years after an extended thymectomy for myasthenia gravis. Eur. J. Cardiothorac. Surg. 33: 1155-1156 [Abstract] [Full Text]  
• Hammond, E R, Pardo, C A, Kerr, D A (2008). Thymic hyperplasia in a patient with recurrent transverse myelitis with clinical resolution after thymectomy. J. Neurol. Neurosurg. Psychiatry 79: 334-335 [Full Text]  
• Amdahl, C., Alseth, E. H., Gilhus, N. E., Nakkestad, H. L., Skeie, G. O. (2007). Polygenic Disease Associations in Thymomatous Myasthenia Gravis. Arch Neurol 64: 1729-1733 [Abstract] [Full Text]  
• Ben-David, H., Sharabi, A., Dayan, M., Sela, M., Mozes, E. (2007). The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc. Natl. Acad. Sci. USA 104: 17459-17464 [Abstract] [Full Text]  
• Tsinzerling, N., Lefvert, A.-K., Matell, G., Pirskanen-Matell, R. (2007). Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J. Neurol. Neurosurg. Psychiatry 78: 1109-1112 [Abstract] [Full Text]  
• Suzuki, S., Utsugisawa, K., Nagane, Y., Satoh, T., Terayama, Y., Suzuki, N., Kuwana, M. (2007). Classification of Myasthenia Gravis Based on Autoantibody Status. Arch Neurol 64: 1121-1124 [Abstract] [Full Text]  
• Gilboa-Geffen, A., Lacoste, P. P., Soreq, L., Cizeron-Clairac, G., Le Panse, R., Truffault, F., Shaked, I., Soreq, H., Berrih-Aknin, S. (2007). The thymic theme of acetylcholinesterase splice variants in myasthenia gravis. Blood 109: 4383-4391 [Abstract] [Full Text]  
• Sheng, J. R., Li, L., Ganesh, B. B., Vasu, C., Prabhakar, B. S., Meriggioli, M. N. (2006). Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. J. Immunol. 177: 5296-5306 [Abstract] [Full Text]  
• DORI, A., SOREQ, H. (2006). Neuromuscular Therapeutics by RNA-Targeted Suppression of ACHE Gene Expression. Ann. N. Y. Acad. Sci. 1082: 77-90 [Abstract] [Full Text]  
• Riedel, R. F., Burfeind, W. R. Jr (2006). Thymoma: Benign Appearance, Malignant Potential. The Oncologist 11: 887-894 [Abstract] [Full Text]  
• Lehmann, H. C., Hartung, H.-P., Hetzel, G. R., Stuve, O., Kieseier, B. C. (2006). Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders.. Arch Neurol 63: 1066-1071 [Abstract] [Full Text]  
• Meraouna, A., Cizeron-Clairac, G., Panse, R. L., Bismuth, J., Truffault, F., Tallaksen, C., Berrih-Aknin, S. (2006). The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108: 432-440 [Abstract] [Full Text]  
• Lehmann, H. C., Hartung, H.-P., Hetzel, G. R., Stuve, O., Kieseier, B. C. (2006). Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders.. Arch Neurol 63: 930-935 [Abstract] [Full Text]  
• Vaidya, H (2006). Case of the month: Unusual presentation of myasthenia gravis with acute respiratory failure in the emergency room. Emerg. Med. J. 23: 410-413 [Abstract] [Full Text]  
• Matsumoto, Y., Matsuo, H., Sakuma, H., Park, I.-K., Tsukada, Y., Kohyama, K., Kondo, T., Kotorii, S., Shibuya, N. (2006). CDR3 Spectratyping Analysis of the TCR Repertoire in Myasthenia Gravis.. J. Immunol. 176: 5100-5107 [Abstract] [Full Text]  
• Rich, M. M. (2006). The Control of Neuromuscular Transmission in Health and Disease. Neuroscientist 12: 134-142 [Abstract]  
• Joudinaud, T. M., Fadel, E., Thomas-de-Montpreville, V., Mussot, S., Flecher, E. M., Dartevelle, P. G. (2006). Fatal giant cell myocarditis after thymoma resection in myasthenia gravis. J. Thorac. Cardiovasc. Surg. 131: 494-495 [Full Text]  
• Cahoon, W. D Jr, Kockler, D. R (2006). Mycophenolate Mofetil Treatment of Myasthenia Gravis. The Annals of Pharmacotherapy 40: 295-298 [Abstract] [Full Text]  
• Vernino, S. (2005). Neurologic autoantibodies: Cautious enthusiasm. Neurology 65: 1688-1689 [Full Text]  
• Duwe, B. V., Sterman, D. H., Musani, A. I. (2005). Tumors of the Mediastinum. Chest 128: 2893-2909 [Abstract] [Full Text]  
• Yang, H., Tuzun, E., Alagappan, D., Yu, X., Scott, B. G., Ischenko, A., Christadoss, P. (2005). IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1. J. Immunol. 175: 2018-2025 [Abstract] [Full Text]  
• Natarajan, N., Weinstein, R. (2005). Therapeutic Apheresis in Neurology Critical Care. J Intensive Care Med 20: 212-225 [Abstract]  
• Bernasconi, P., Barberis, M., Baggi, F., Passerini, L., Cannone, M., Arnoldi, E., Novellino, L., Cornelio, F., Mantegazza, R. (2005). Increased Toll-Like Receptor 4 Expression in Thymus of Myasthenic Patients with Thymitis and Thymic Involution. Am. J. Pathol. 167: 129-139 [Abstract] [Full Text]  
• Felice, K. J., DiMario, F. J., Conway, S. R. (2005). Postinfectious Myasthenia Gravis: Report of two Children. J Child Neurol 20: 441-444 [Abstract]  
• Scherer, K., Bedlack, R. S., Simel, D. L. (2005). Does This Patient Have Myasthenia Gravis?. JAMA 293: 1906-1914 [Abstract] [Full Text]  
• Konishi, T, Yoshiyama, Y, Takamori, M, Saida, T, the Japanese FK506 MG Study Group, (2005). Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J. Neurol. Neurosurg. Psychiatry 76: 448-450 [Abstract] [Full Text]  
• Granetzny, A., Hatem, A., Shalaby, A., Boseila, A. (2005). Manubriotomy versus median sternotomy in thymectomy for myasthenia gravis. Evaluation of the pulmonary status. Eur. J. Cardiothorac. Surg. 27: 361-366 [Abstract] [Full Text]  
• Thanvi, B R, Lo, T C N (2004). Update on myasthenia gravis. Postgrad. Med. J. 80: 690-700 [Abstract] [Full Text]  
• Dawson, L. J., Allison, H. E., Stanbury, J., Fitzgerald, D., Smith, P. M. (2004). Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 43: 1488-1495 [Abstract] [Full Text]  
• Vandiedonck, C., Beaurain, G., Giraud, M., Hue-Beauvais, C., Eymard, B., Tranchant, C., Gajdos, P., Dausset, J., Garchon, H.-J. (2004). Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc. Natl. Acad. Sci. USA 101: 15464-15469 [Abstract] [Full Text]  
• Ota, T., Aoki-Ota, M., Tsunoda, K., Simoda, K., Nishikawa, T., Amagai, M., Koyasu, S. (2004). Auto-reactive B cells against peripheral antigen, desmoglein 3, escape from tolerance mechanism. Int Immunol 16: 1487-1495 [Abstract] [Full Text]  
• van Lunteren, E., Moyer, M., Kaminski, H. J. (2004). Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance. J. Appl. Physiol. 97: 895-901 [Abstract] [Full Text]  
• Zielinski, M., Kuzdzal, J., Staniec, B., Harazda, M., Nabialek, T., Pankowski, J., Szlubowski, A., Medon, J. (2004). Safety for preoperative use of steroids for transsternal thymectomy in myasthenia gravis. Eur. J. Cardiothorac. Surg. 26: 407-411 [Abstract] [Full Text]  
• Selcen, D., Fukuda, T., Shen, X.-M., Engel, A. G. (2004). Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 62: 1945-1950 [Abstract] [Full Text]  
• Dalakas, M. C. (2004). Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA 291: 2367-2375 [Abstract] [Full Text]  
• Detterbeck, F. C., Parsons, A. M. (2004). Thymic tumors. Ann. Thorac. Surg. 77: 1860-1869 [Abstract] [Full Text]  
• Lopez-Cano, M., Ponseti-Bosch, J. M., Espin-Basany, E., Sanchez-Garcia, J. L., Armengol-Carrasco, M. (2003). Clinical and pathologic predictors of outcome in Thymoma-Associated myasthenia gravis. Ann. Thorac. Surg. 76: 1643-1649 [Abstract] [Full Text]  
• Wang, H.-S. (2003). Myasthenia Gravis: Generalized vs Ocular, and Children vs Adults. Arch Neurol 60: 1491-1491 [Full Text]  
• VERNINO, S., LENNON, V. A. (2003). Neuronal Ganglionic Acetylcholine Receptor Autoimmunity. Ann. N. Y. Acad. Sci. 998: 211-214 [Abstract] [Full Text]  
• MARX, A., MULLER-HERMELINK, H. K., STROBEL, P. (2003). The Role of Thymomas in the Development of Myasthenia Gravis. Ann. N. Y. Acad. Sci. 998: 223-236 [Abstract] [Full Text]  
• MILANI, M., OSTLIE, N., WANG, W., CONTI-FINE, B. M. (2003). T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia Gravis. Ann. N. Y. Acad. Sci. 998: 284-307 [Abstract] [Full Text]  
• WANG, W., MILANI, M., OKITA, D., OSTLIE, N., CONTI-FINE, B. M. (2003). Epitope Repertoire of Th1 and Th2 Cells Reactive with the Mouse Muscle AChR {alpha} Subunit in C57Bl/6 Mice. Ann. N. Y. Acad. Sci. 998: 384-387 [Full Text]  
• RICHMAN, D. P., AGIUS, M. A. (2003). Treatment Principles in the Management of Autoimmune Myasthenia Gravis. Ann. N. Y. Acad. Sci. 998: 457-472 [Abstract] [Full Text]  
• TELLEZ-ZENTENO, J. F., REMES-TROCHE, J. M., GARCIA-RAMOS, G., ESTANOL, B., GARDUNO-ESPINOZA, J. (2003). Prognostic Factors of Thymectomy in Patients with Myasthenia Gravis: A Cohort of 132 Patients. Ann. N. Y. Acad. Sci. 998: 491-493 [Full Text]  
• Hue, S., Monteiro, R. C., Berrih-Aknin, S., Caillat-Zucman, S. (2003). Potential Role of NKG2D/MHC Class I-Related Chain A Interaction in Intrathymic Maturation of Single-Positive CD8 T Cells. J. Immunol. 171: 1909-1917 [Abstract] [Full Text]  
• Shiono, H., Wong, Y. L., Matthews, I., Liu, J.-L., Zhang, W., Sims, G., Meager, A., Beeson, D., Vincent, A., Willcox, N. (2003). Spontaneous production of anti-IFN-{alpha} and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 15: 903-913 [Abstract] [Full Text]  
• Paas-Rozner, M., Sela, M., Mozes, E. (2003). A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells. Proc. Natl. Acad. Sci. USA 100: 6676-6681 [Abstract] [Full Text]  
• VINCENT, A., DALTON, P., CLOVER, L., PALACE, J., LANG, B. (2003). Antibodies to Neuronal Targets in Neurological and Psychiatric Diseases. Ann. N. Y. Acad. Sci. 992: 48-55 [Abstract] [Full Text]  
• Ashton, R. C. Jr, McGinnis, K. M., Connery, C. P., Swistel, D. G., Ewing, D. R., DeRose, J. J. Jr (2003). Totally endoscopic robotic thymectomy for myasthenia gravis. Ann. Thorac. Surg. 75: 569-571 [Abstract] [Full Text]  
• BRENNER, T., HAMRA-AMITAY, Y., EVRON, T., BONEVA, N., SEIDMAN, S., SOREQ, H. (2003). The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 17: 214-222 [Abstract] [Full Text]  
• Ostlie, N., Milani, M., Wang, W., Okita, D., Conti-Fine, B. M. (2003). Absence of IL-4 Facilitates the Development of Chronic Autoimmune Myasthenia Gravis in C57BL/6 Mice. J. Immunol. 170: 604-612 [Abstract] [Full Text]  
• Abicht, A., Lochmuller, H. (2002). What's in the serum of seronegative MG and LEMS?: MuSK et al.. Neurology 59: 1672-1673 [Full Text]  
• Plested, C.P., Tang, T., Spreadbury, I., Littleton, E.T., Kishore, U., Vincent, A. (2002). AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 59: 1682-1688 [Abstract] [Full Text]  
• de Perrot, M., Liu, J., Bril, V., McRae, K., Bezjak, A., Keshavjee, S. H. (2002). Prognostic significance of thymomas in patients with myasthenia gravis. Ann. Thorac. Surg. 74: 1658-1662 [Abstract] [Full Text]  
• Werner, P, Kiechl, S, Thaler, C, Willeit, J, Poewe, W, Baldissera, I (2002). A relapsing-remitting type of ocular myasthenia gravis without typical muscle fatiguability. J. Neurol. Neurosurg. Psychiatry 73: 205-205 [Full Text]  
• Reyes-Reyna, S., Stegall, T., Krolick, K. A. (2002). Muscle Responds to an Antibody Reactive with the Acetylcholine Receptor by Up-Regulating Monocyte Chemoattractant Protein 1: A Chemokine with the Potential to Influence the Severity and Course of Experimental Myasthenia Gravis. J. Immunol. 169: 1579-1586 [Abstract] [Full Text]  
• Jander, S., Stoll, G. (2002). Increased serum levels of the interferon-{gamma}-inducing cytokine interleukin-18 in myasthenia gravis. Neurology 59: 287-289 [Abstract] [Full Text]  
• Deng, C., Goluszko, E., Tuzun, E., Yang, H., Christadoss, P. (2002). Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production. J. Immunol. 169: 1077-1083 [Abstract] [Full Text]  
• Pego-Fernandes, P. M., de Campos, J. R. M., Jatene, F. B., Marchiori, P., Suso, F. V., de Oliveira, S. A. (2002). Thymectomy by partial sternotomy for the treatment of myasthenia gravis. Ann. Thorac. Surg. 74: 204-208 [Abstract] [Full Text]  
• Strobel, P., Helmreich, M., Menioudakis, G., Lewin, S. R., Rudiger, T., Bauer, A., Hoffacker, V., Gold, R., Nix, W., Schalke, B., Elert, O., Semik, M., Muller-Hermelink, H. K., Marx, A. (2002). Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4+ T cells in thymomas. Blood 100: 159-166 [Abstract] [Full Text]  
• Giraud, M., Beaurain, G., Yamamoto, A. M., Eymard, B., Tranchant, C., Gajdos, P., Garchon, H.-J. (2001). Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 57: 1555-1560 [Abstract] [Full Text]  
• Buckley, C., Newsom-Davis, J., Willcox, N., Vincent, A. (2001). Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 57: 1579-1582 [Abstract] [Full Text]  
• Higuchi, T., Taki, J., Kinuya, S., Yamada, M., Kawasuji, M., Matsui, O., Nonomura, A., Bunko, H., Tonami, N. (2001). Thymic Lesions in Patients with Myasthenia Gravis: Characterization with Thallium 201 Scintigraphy. Radiology 221: 201-206 [Abstract] [Full Text]  
• Shi, F.-D., Flodstrom, M., Kim, S. H., Pakala, S., Cleary, M., Ljunggren, H.-G., Sarvetnick, N. (2001). Control of the Autoimmune Response by Type 2 Nitric Oxide Synthase. J. Immunol. 167: 3000-3006 [Abstract] [Full Text]  
• Sims, G. P., Shiono, H., Willcox, N., Stott, D. I. (2001). Somatic Hypermutation and Selection of B Cells in Thymic Germinal Centers Responding to Acetylcholine Receptor in Myasthenia Gravis. J. Immunol. 167: 1935-1944 [Abstract] [Full Text]  
• Yamamoto, A. M., Gajdos, P., Eymard, B., Tranchant, C., Warter, J.-M., Gomez, L., Bourquin, C., Bach, J.-F., Garchon, H.-J. (2001). Anti-Titin Antibodies in Myasthenia Gravis: Tight Association With Thymoma and Heterogeneity of Nonthymoma Patients. Arch Neurol 58: 885-890 [Abstract] [Full Text]  
• Wang, H.-B., Shi, F.-D., Li, H., Chambers, B. J., Link, H., Ljunggren, H.-G. (2001). Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis. J. Immunol. 166: 6430-6436 [Abstract] [Full Text]  
• Dunsire, M. F., Clarke, S. G., Stedmon, J. J. (2001). Undiagnosed myasthenia gravis unmasked by neuromuscular blockade. Br J Anaesth 86: 727-730 [Abstract] [Full Text]  
• Deng, C., Goluszko, E., Christadoss, P. (2001). Fas/Fas Ligand Pathway, Apoptosis, and Clonal Anergy Involved in Systemic Acetylcholine Receptor T Cell Epitope Tolerance. J. Immunol. 166: 3458-3467 [Abstract] [Full Text]  
• FABER-ELMANN, A., GRABOVSKY, V., DAYAN, M., SELA, M., ALON, R., MOZES, E. (2001). An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope. FASEB J. 15: 187-194 [Abstract] [Full Text]  
• Suzuki, M., Yoshii, T., Ohtsuka, T., Sasaki, O., Hara, Y., Okura, T., Shigematsu, Y., Hamada, M., Hiwada, K. (2000). Coronary Spastic Angina Induced by Anticholinesterase Medication for Myasthenia Gravis: A Case Report. ANGIOLOGY 51: 1031-1034 [Abstract]  
• Faber-Elmann, A., Grabovsky, V., Dayan, M., Sela, M., Alon, R., Mozes, E. (2000). Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. Int Immunol 12: 1651-1658 [Abstract] [Full Text]  
• Briassoulis, G., Hatzis, T., Liakopoulou, T., Youroukos, S. (2000). Continuous Neostigmine Infusion in Post-Thymectomy Juvenile Myasthenic Crisis. J Child Neurol 15: 747-749 [Abstract]  
• Tsao, C.-Y., Mendell, J. R., Lo, W. D., Luquette, M., Rennebohm, R. (2000). Myasthenia Gravis and Associated Autoimmune Diseases in Children. J Child Neurol 15: 767-769 [Abstract]  
• Wang, H.-B., Li, H., Shi, F.-D., Chambers, B. J., Link, H., Ljunggren, H.-G. (2000). Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 12: 1381-1388 [Abstract] [Full Text]  
• Vernino, S., Low, P. A., Fealey, R. D., Stewart, J. D., Farrugia, G., Lennon, V. A. (2000). Autoantibodies to Ganglionic Acetylcholine Receptors in Autoimmune Autonomic Neuropathies. NEJM 343: 847-855 [Abstract] [Full Text]  
• Gultekin, S. H., Rosenfeld, M. R., Voltz, R., Eichen, J., Posner, J. B., Dalmau, J. (2000). Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123: 1481-1494 [Abstract] [Full Text]  
• Siao, P., Zukerberg, L. R. (2000). Case 15-2000- A 69-Year-Old Man with Myasthenia Gravis and a Mediastinal Mass. NEJM 342: 1508-1514 [Full Text]  
• Kaminski, H. J., Daroff, R. B. (2000). Treatment of Ocular Myasthenia: Steroids Only When Compelled. Arch Neurol 57: 752-753 [Full Text]  
• Komiyama, A., Arai, H., Kijima, M., Hirayama, K. (2000). Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 68: 214-217 [Abstract] [Full Text]  
• Vernino, S., Auger, R. G., Emslie-Smith, A. M., Harper, C. M., Lennon, V. A. (1999). Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology 53: 1233-1233 [Abstract] [Full Text]  
• Thomas, C. R., Wright, C. D., Loehrer, P. J. (1999). Thymoma: State of the Art. JCO 17: 2280-2280 [Abstract] [Full Text]  
• Saoudi, A., Bernard, I., Hoedemaekers, A., Cautain, B., Martinez, K., Druet, P., De Baets, M., Guery, J.-C. (1999). Experimental Autoimmune Myasthenia Gravis May Occur in the Context of a Polarized Th1- or Th2-Type Immune Response in Rats. J. Immunol. 162: 7189-7197 [Abstract] [Full Text]  
• Shi, F.-D., Li, H., Wang, H., Bai, X., van der Meide, P. H., Link, H., Ljunggren, H.-G. (1999). Mechanisms of Nasal Tolerance Induction in Experimental Autoimmune Myasthenia Gravis: Identification of Regulatory Cells. J. Immunol. 162: 5757-5763 [Abstract] [Full Text]  
• Ringel, S. P. (1999). Practicing neurology: A delicate balance. Neurology 52: 1526-1526 [Full Text]  
• Zhang, G.-X., Xiao, B.-G., Bai, X.-F., van der Meide, P. H., Orn, A., Link, H. (1999). Mice with IFN-{gamma} Receptor Deficiency Are Less Susceptible to Experimental Autoimmune Myasthenia Gravis. J. Immunol. 162: 3775-3781 [Abstract] [Full Text]  
• Reinhardt, C., Melms, A. (1999). Elevated frequencies of natural killer T lymphocytes in myasthenia gravis. Neurology 52: 1485-1485 [Abstract] [Full Text]  
• Nations, S. P., Wolfe, G. I., Amato, A. A., Jackson, C. E., Bryan, W. W., Barohn, R. J. (1999). Distal myasthenia gravis. Neurology 52: 632-632 [Abstract] [Full Text]  
• Faber-Elmann, A., Paas-Rozner, M., Sela, M., Mozes, E. (1998). Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes. Proc. Natl. Acad. Sci. USA 95: 14320-14325 [Abstract] [Full Text]  
• Dalmau, J. O., Posner, J. B. (1998). Neurological Paraneoplastic Syndromes. Neuroscientist 4: 443-453  
• RUFF, R. L. (1998). Electrophysiology of Postsynaptic Activation. Ann. N. Y. Acad. Sci. 841: 57-70 [Full Text]  
• LINDSTROM, J., PENG, X., KURYATOV, A., LEE, E., ANAND, R., GERZANICH, V., WANG, F., WELLS, G., NELSON, M. (1998). Molecular and Antigenic Structure of Nicotinic Acetylcholine Receptors. Ann. N. Y. Acad. Sci. 841: 71-86 [Full Text]  
• DRACHMAN, D. B., McINTOSH, K. R., YANG, B. (1998). Factors That Determine the Severity of Experimental Myasthenia Gravisa. Ann. N. Y. Acad. Sci. 841: 262-282 [Full Text]